Abstract:Objective:To study the effect of autologous hematopoietic stem cell transplantation (ASCT) as a consolidation therapy for newly diagnosed extramedullary multiple myeloma (EMM) and its effect on survival.Methods:The clinical features, treatment, efficacy and survival of 55 patients with newly diagnosed EMM who were eligible for ASCT from May 2013 to September 2019 in the First Affiliated Hospital, School of Medicine, Zhejiang University, were retrospectively analyzed. All the EMM patients received bortezomib-based induction therapy regimen and were divided into ASCT group (n=14) and no ASCT group (n=41) according to whether or not the ASCT was performed as a consolidation therapy. The evaluative criterias set down by International Myeloma Working Group were used to evaluate the curative effect including complete remission, very good partial response, partial response, stable disease and progressive disease. The abnormal distribution measurement data between ASCT group and no ASCT group were compared by Mann-Whitney U test, and the enumeration data between the 2 groups were compared with chi-square test and Fisher exact probality test. The Kaplan-Meier method was used to draw the survival curve of the 2 groups and the log-rank test was used to compare. The Cox proportional hazard model was used to analyse the influence factors of progress free survive (PFS) and overall survival (OS). P<0.05 was considered statistically significant.Results:The median age of the 55 EMM patients were 57 years old (31-65 years old). There were 49 cases of extramedullary-bone related and 6 cases of extramedullary-extraosseous. The difference of the curative effect after consolidation therapy between ASCT group and no ASCT group after consolidation therapy had no statistical significance (χ2=2.808, P>0.05), but the difference of the curative effect between the 2 groups was statistically significant (χ2=6.946, P<0.05). The EMM patients were followed until June 30, 2020, and the median PFS of ASCT group were 46.0 months (95%CI: 29.0-63.1), and the PFS rates of 1, 3, 5 year were 92.3%, 60.2% and 30.1%; the median PFS of no ASCT group were 18.8 months (95%CI: 11.3-26.3), and the 1, 3, 5 year PFS rates of patients were 72.5%, 36.3% and 24.2%, and the PFS rates between the 2 groups had no statistical significance (all P>0.05). The median OS of ASCT were not reached by the end of follow-up, and the 1, 3, 5 year OS rate of patients were all 100%; the median OS of no ASCT were 43.6 months (95%CI: 38.9-57.5), and the 1, 3, 5 year OS rates of patients were 87.8%, 60.3% and 48.4%, and the OS between the 2 groups had statistical significance (χ2=5.838, P<0.05). The result of multivariate analysis indicated that the EMM type and ASCT were independent factors of PFS in newly diagnosed EMM patients (HR=4.11 and 2.81, all P<0.05); and the EMM type was an independent risk factor of OS in neuly diagnosed EMM patients (HR=5.23, P<0.05).Conclusions:ASCT can significantly improve the PFS and OS of newly diagnosed EMM patients treated with bortezomib, and it is an independent prognostic factor for PFS. The type of EMM is the independent prognostic factors for PFS and OS of newly diagnosed patients with EMM. However, it still necessary to expand the cases and conduct prospective studies to further confirm.

Efficacy and prognostic factors of autologous hematopoietic stem cell transplantation for multiple myeloma:clinical analysis of 53 cases

Evaluation of clinical efficacy and prognostic factors in multiple myeloma patients treated with auto-HSCT:A single-center real-world study

[Long Term Curative Effects and Prognostic Analysis of Stem Cell Transplantation for Treating Patients with Peripheral T Cell Lymphoma].

[A Multi-Centers Clinical Study of Different Treatment Outcomes of 332 Patients with Multiple Myeloma].

[The Impact of Autologous Stem Cell Transplantation on the Prognosis in Multiple Myeloma].

Treatment options and prognosis in newly diagnosed multiple myeloma patients]

Clinical Analysis of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years

The key factors influencing patients in selecting autologous hematopoietic stem-cell transplantation as the main therapy for multiple myeloma: A population-based epidemiological study

The effects of autologous hemetopoietic stem cell transplantation( Auto-HSCT) for malignant lymphoma

New agents-based induction chemotherapy followed by autologous stem cell transplantation and maintenance treatment strategy for multiple myeloma: a single center retrospective study of 300 cases

Efficacy of autologous hematopoietic stem cell transplantation in the treatment of extramedullary multiple myeloma

Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation

Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)

Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation]

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Bortezomib-based Induction Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation and Maintenance in 200 Patients with Multiple Myeloma: Long-Term Follow-Up Results from Single Center

[Clinical analysis of 81 cases of malignant lymphoma treated with autologous hematopoietic stem cell transplantation].

Determining the Optimal Time for Bortezomib-Based Induction Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplant in the Treatment of Multiple Myeloma.

Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913)